Bristol-Myers Squibb (BMS) has launched a scientific initiative to improve clinical outcomes for HIV/AIDS, hepatitis B virus (HBV) and hepatitis C virus (HCV), according to a BMS statement. The “Partnering for Cure” program provides researchers and clinicians with a forum to discuss cure-related topics. The initiative is led by an expert panel from across Europe. As part of the program, BMS also will support three research projects focused on improving current understandings of HIV, HBV and HCV, as well as creating novel cure strategies. Applications will be accepted online until October 31.

To read the statement, visit